Uni-Bio Science Group (HK690) 联康生物科技集团

Uni-Bio Science Group Limited is a company listed on the main board of The Stock Exchange of Hong Kong (SEHK: 0690). The core business of the Company and its subsidiaries is the R&D, manufacturing and sales of innovative biologic products that treat human diseases. Uni-Bio is headquartered in Hong Kong and its main operations are in mainland China. The Group is strongly focused on R&D and has highly qualified team located in Guangdong province. It also has two GMP-certified manufacturing facilities in Beijing and Shenzhen, manufacturing the company’s marketed products - Voriconazole and EGF franchise, respectively. Currently, the Group has two new prescription drugs that have completed all clinical trials –rhExtendin-4 and rhPTH 1-34. The Group’s corporate philosophy is to achieve better human health by bringing high quality science and treatment to patients. To this end, the Group is deeply dedicated to serving patients better through partnering. Ultimately, becoming the “Partner of Choice” in China, bringing cost-effective and important treatments into China.